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I. Summary 
GABAA receptors are the major inhibitory transmitter receptors in the brain and the site 
of action of many clinically important drugs, such as benzodiazepines, barbiturates, 
anesthetics and convulsants. The majority of GABAA receptors are composed of two alpha 
(α), two beta (β) and one gamma (γ) subunit. The two GABA binding sites are located at the 
two extracellular β-plus/α-minus interfaces whereas the binding site for benzodiazepines is 
located at the homologous α-plus/γ-minus interface. Despite the extensive clinical use of 
benzodiazepines, the molecular basis of their interaction with the GABAA receptor, as well 
as the protein structure of the benzodiazepine binding site is not known. 
To obtain information on the structural requirements of the benzodiazepine binding site, we 
investigated whether it is possible to engineer a benzodiazepine binding site into α1β3 
receptors, which presumably are composed of two α1 and three β3 subunits and have no high 
affinity benzodiazepine binding site. To achieve this task, the β3-minus side had to be 
converted at least partially to a γ2-minus side. Using a structural model of the diazepam-
bound benzodiazepine binding site as a template, that was recently developed by our group, 
as well as previously published mutagenesis data, we introduced several amino acid residues 
of the γ2-minus side that are important for benzodiazepine binding, into the β3-minus side of 
an α1β3 GABAA receptor.  
Benzodiazepine affinity was studied by radioligand binding assays with appropriately 
transfected human embryonic kidney cells, whilst modulation of the mutated recombinant 
receptors was investigated by the two electrode voltage clamp method in Xenopus laevis 
oocytes. Results indicate that by using four mutations (β3DGE) we were able to introduce a 
high affinity benzodiazepine binding site into the α1β3 model system. Furthermore, we were 
able to show that the GABA currents of the mutated recombinant receptors α1β3DG (three 
mutations), and α1β3DGE, could be modulated by Ro15-1788 and flurazepam. 
   
 5 
 
II. Zusammenfassung 
GABAA Rezeptoren sind die wichtigsten inhibitorischen Neurotransmitter Rezeptoren 
des Säugetier Gehirns, und werden durch GABA (γ-Aminobuttersäure) aktiviert. Zahlreiche 
klinisch relevante Wirkstoffe wie Benzodiazepine, Barbiturate, Anästhetika können neben 
GABA an den GABAA Rezeptor binden und seine Wirkung modulieren. Obwohl diese 
Wirkstoffe in der Medizin eine breite Anwendung finden, ist die genaue Struktur der 
Bindungsstelle nicht bekannt. Dies macht ihn zu einem hoch interessanten 
Untersuchungsgegenstand der Neurobiologie. 
GABAA Rezeptoren bestehen aus fünf Untereinheiten. Die Mehrheit der Rezeptoren sind aus 
einer gamma (γ), zwei alpha (α), und zwei beta (β) Untereinheiten zusammengesetzt, wobei 
die hoch affine Bindung von Benzodiazepinen das Vorhandensein einer gamma Untereinheit 
voraussetzt. Jede Untereinheit hat per Definition eine plus und eine minus Seite. Die 
Benzodiazepin Bindungstelle befindet sich im extrazellulären Bereich zwischen der α-plus 
und der γ-minus Seite dieser Untereinheiten. 
Das Ziel dieser Arbeit war es, eine hoch affine Benzodiazepin Bindungsstelle in einen α1β3 
Rezeptor einzubauen, der im Gegensatz zu einem α1β3γ2 Rezeptor keine solche besitzt. Der 
α1β3 Rezeptor besteht aus zwei α und drei β Untereinheiten. Der Reihe nach wurden 
wichtige Aminosäuren der γ-minus Seite (eines α1β3γ2 Rezeptors) in die β-minus Seite des 
α1β3 Rezeptors eingebaut. Diese Aminosäuren wurden mittels eines in unserem Labor 
entwickelten strukturellen Modells der Diazepam-gebundenen Benzodiazepin Bindungsstelle 
und mittels bereits publizierter Artikel ausgewählt. 
Die Affinität von Benzodiazepinen wurde durch Radioliganden-Bindungsstudien an 
Membranen von HEK Zellen bestimmt die mit den entsprechenden Rezeptoren transfiziert 
worden waren. Die erhaltenen Resultate lassen darauf schließen, dass vier Mutationen 
(β3DGE) ausreichten, um eine hochaffine Benzodiazepin Bindungsstelle in die α1β3 
Rezeptoren einzubauen. Die pharmakologische Charakterisierung wurde mittels einer zwei 
Elektroden Spannungsklemme in Xenopus laevis Oozyten vorgenommen. Die Ergebnisse 
zeigen, dass sich die durch Flurazepam und Ro15-1788 ausgelöste Modulation der GABA 
Ströme der rekombinanten Rezeptoren α1β3DG  (dreifach Mutante) und α1β3DGE von der 
des Wildtyp α1β3 Rezeptors unterscheidet. 
Ich habe mich bemüht, sämtliche Inhaber der Bildrechte ausfindig zu machen und Ihre Zustimmung zur 
Verwendung der Bilder in dieser Arbeit eingeholt. 
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 IV. Abbrevations 
APS   Ammoniumpersulfate  
Bmax    Maximal binding site density
 
 
BCA   Bicinchoninic acid  
Bp   Base pair 
BZ   Benzodiazepine  
cDNA  Complementary Desoxyribonucleic acid 
E.coli  Escherichia Coli 
EDTA   Ethylenediaminetetraacetic acid  
GABA   γ-Aminobutyricacid  
HEPES  N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid  
KD   Ligand concentration where 50% of all receptors are occupied 
kDa   Kilo Dalton  
Ki  Equilibrium dissociation constant of the unlabeled ligand 
Min.  Minute 
mM  millimolar 
MOPS   N-Morpholino propanesulfonic acid  
µM  micromolar 
nAChR  Nicotinic acetylcholine receptor 
nM  nanomolar 
PAGE   Polyacrylamide gel electrophoresis  
PBS   Phosphate buffered saline  
pLGIC   Pentameric Ligand Gated Ion channels 
PVDF   Polyvinylidene fluoride  
SDS   Sodium dodecyl sulphate  
Sec.  Second 
SEM   Standard error of mean  
TEMED  N,N,N´,N´-tetra-methyl-ethylene-diamine  
TM  Trans membrane  
Tris   Tris (hydroxymethyl) aminoethane  
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1. INTRODUCTION 
1.1.Cys-Loop Receptor Family 
GABAA receptors belong to the family of the Cys-loop pentameric ligand gated 
ion channel receptors (pLGIC). All members of this superfamily share a homologous 
13 amino acid residue long “loop” at the extracellular domain which is flanked by a 
disulfide bridge (Karlin 2002; Sixma 2007). PLGIC can be divided into cation-
selective excitatory receptors, such as the nicotinic acetylcholine receptors (nAChR), 
the ionotrophic 5-HT3 receptors and a Zn2+ activated ion channel, and anion-
selective inhibitory ones, such as the glycine receptors and the GABAA receptors 
(Olsen and Sieghart 2008). Members of this superfamily use similar sequences and 
functional domains to establish receptor structure and functionality (Olsen and 
Sieghart 2008): As shown in Fig.1.1, each subunit consists of an N-terminal 
extracellular domain region containing a cys-loop, four transmembrane α-helices, of 
which TM2 forms the lining of the ion channel, a large intracellular loop between 
TM3-TM4 and an extracellular C-terminal end.  
 
Fig. 1.1: Membrane organization of a subunit from the pLGIC family (Jacob, Moss et 
al. 2008). 
Detailed knowledge about their protein structure is of great research interest, as they 
are pharmacologically relevant. 1988 the first structural information on near 
crystalline arrays of the nAChR in the electric ray Torpedo became available 
(Unwin, Toyoshima et al. 1988; Toyoshima and Unwin 1990). 2001 the crystal 
structure of the acetylcholine binding protein (AChBP), a water-soluble protein 
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homologous to the extracellular part of nAChR from snail, was published (Brejc, van 
Dijk et al. 2001). Then, low-resolution electron microscopy images at 4Å of the 
nAChR were published (Miyazawa, Fujiyoshi et al. 2003; Unwin 2005), and in 2007 
the high-resolution crystal structure of the extracellular ligand binding domain of a 
single AChR subunit was revealed (Dellisanti, Yao et al. 2007). Recently, the first 
prokaryotic receptor belonging to the family of pLGIC could be crystallized and 
revealed an extracellular organization similar to that of the AChBP in eukaryotes 
(Hilf and Dutzler 2008; Hilf and Dutzler 2009). In spite of great efforts, so far it was 
not possible to crystallize the GABAA receptor or other receptors of the mammalian 
pLGIC. 
All models of the extracellular and transmembrane domains of the GABAA receptor 
used in our laboratory, were based on the published AChBP and nAChR crystal 
structures and validated by computational methods (Ernst, Brauchart et al. 2003; 
Ernst, Bruckner et al. 2005; Richter submitted). This is possible, as the sequence 
identity of the subunit members of the pLGIC is 20-30% (Olsen and Sieghart 2008), 
although there is a significant variability in the local interface and pocket structure 
between the different members of the superfamily (Richter submitted). Functional 
homology at the secondary and tertiary level was suggested to be higher, as receptors 
use similar domains for channel structure, agonist binding and allosteric ligands 
(Olsen and Sieghart 2008). Furthermore, there is evidence that GABA and 
acetylcholine bind at a similar subunit interface, involving homologous amino acid 
residues (Olsen, Chang et al. 2004). These findings are of particular interest when 
revealing the ligand binding sites, possible domain interactions and conformational 
changes (Olsen, Chang et al. 2004) of the GABAA receptor, because of their medical 
implications in pharmacological drug developmental studies. 
 
1.2.GABAA Receptor 
Gamma-Aminobutyric acid (GABA) is the most important inhibitory 
neurotransmitter in the central nervous system and exerts most of its actions via 
GABAA receptors (Sieghart 1995). The GABAergic synaptic transmission is central 
to neuronal activity and information processing in the mammalian brain (Minelli, 
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Brecha et al. 1995). GABA is synthesized by the decarboxylation of glutamate by the 
enzyme glutamic acid decarboxylase (Bear 2001) as shown in Fig. 1.2, whereas 
glutamate is a citric acid cycle intermediate, produced in the mitochondrion. GABA 
is stored in vesicles of the presynaptic terminals of neurons, released into the 
synaptic cleft upon depolarization of the presynaptic membrane and subsequent 
intracellular Ca2+ increase and binds to receptors on the postsynaptic membrane. 
GABA transporters, localized at neurons and glia cells, re-accumulate released 
transmitters into presynaptic terminals and glia cells. GABA is either re-used after 
accumulation into vesicles by vesicular transporters or metabolized by GABA-
transaminase, for further usage in the citric acid cycle (Minelli, Brecha et al. 1995; 
Bear 2001). 
 
Fig. 1.2: GABA synthesis by the decarboxylation of glutamate (Bear 2001). 
There are two GABA receptor types by which the action of GABA can be mediated: 
The ionotropic GABAA receptors and the metabotropic GABAB receptors. 
Occasionally in the literature GABAC receptors are mentioned; but these are 
ionotrophic GABAA receptors composed of rho (ρ) subunits (Olsen and Sieghart 
2009).  
GABAA receptors can be stimulated by GABA, muscimol and isoguvacine and 
inhibited noncompetitively by picrotoxin and competitively by bicuculline (Sieghart 
1995). Ionotrophic GABAA receptors are pentameric receptors that can be composed 
of up to five different subunits (Tretter, Ehya et al. 1997; Klausberger, Sarto et al. 
2001) that directly form an anion-selective channel. Upon binding of GABA, the 
receptors increase their neuronal membrane conductance for Cl- ions, and as the Cl- 
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ion concentration within the cell is normally lower than outside, the opening of the 
channel forces Cl- ions into the cell (Sieghart 1995). This leads to rapid inhibitory 
currents causing hyperpolarization and a reduction of neuronal excitability (Olsen 
and Sieghart 2008). In early development as well as under conditions of disease, 
when the Cl- equilibrium potential is less negative than the resting membrane 
potential of the cell, receptor activation can increase neuronal excitability (Olsen and 
Sieghart 2008). 
Metabotrophic GABAB receptors are heterodimeric G-protein-coupled receptors 
composed of GABAB1 and GABAB2 subunits. They can be located pre- and 
postsynaptically and are coupled to Ca2+ and K+ channels, respectively. Activation of 
presynaptic GABAB receptors can close Ca2+ channels, leading to inhibition of 
transmitter release. Activation of postsynaptic GABAB receptors can activate K+ 
channels leading to neuronal hyperpolarization (Bowery 2006). These receptors can 
be stimulated by GABA or (-)baclofen and inhibited by phaclofen (Sieghart 1995).  
The metabotropic GABAB receptors can be distinguished from faster opening 
ionotrophic GABAA receptors by their different kinetics in the inhibitory post 
synaptic potentials (IPSPs).  
 
1.3.Receptor Structure  
There are in sum 19 different mammalian GABAA receptor subunit genes 
identified: 6α, 3β, 3γ, 1δ, 1ε, 1π, 1θ, 3ρ and furthermore there exist some subunit 
splice variants predominantly within the γ2 subunit: γ2L (large), γ2S (small). There 
is a large number of possible subunit combinations, but only very few have been 
unequivocally identified (Olsen and Sieghart 2008). The most abundant subunit 
composition of the GABAA receptor consists of one γ, two α, and two β subunits, 
forming the functional heteropentameric receptor, indicated in Fig. 1.3 (A) (Sieghart 
1995; Tretter, Ehya et al. 1997; Klausberger, Ehya et al. 2001). The formation of 
pentameric receptors consisting of only one or two subunits is also possible, although 
with a lower assembly efficiency (Sieghart 1995; Tretter, Ehya et al. 1997).  
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Similar to nAChR, GABAA receptors are allosteric receptors, carrying multiple 
agonist-binding sites (Karlin 2002). GABA and benzodiazepines bind at subunit 
interfaces of the predominantly β-stranded extracellular domains, which are formed 
by a plus side of one, and a minus side of another subunit (Monod, Wyman et al. 
1965; Ernst, Brauchart et al. 2003) as shown in Fig 1.3 (B).  
 
Fig. 1.3: (A) Subunit composition of the functional heteropentameric GABAA receptor, 
modified from Olsen (Olsen and Sieghart 2008). (B) Model of the extracellular part of 
the GABAA Receptor viewed from above, with possible ligand binding sites indicated as 
arrows. Modified from Klausberger and Ernst (Klausberger, Sarto et al. 2001; Ernst, 
Bruckner et al. 2005). GABA binding sites are indicated as black, the benzodiazepine 
binding site as light blue circles. 
The two GABA binding sites are located at the β-plus/α-minus interface. High 
affinity binding of classical benzodiazepines requires the minus site of the γ2 subunit 
(Pritchett, Sontheimer et al. 1989) together with the plus site of one of the α1,2,3, or 
5 subunits (Olsen, Chang et al. 2004). A low affinity binding site for the 
benzodiazepine flurazepam was additionally found at the α-plus/β-minus interface 
(Baur, Tan et al. 2008). Many key elements of agonist and drug action seem to be 
located at the interface of the minus and the plus side of two subunits (Ernst, 
Bruckner et al. 2005). 
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1.4.GABAA Receptor Pharmacology  
GABAA receptors are the target of a large variety of clinically and 
pharmacologically important drugs such as benzodiazepines, barbiturates, anesthetics 
and convulsants. They bind at allosteric binding sites of the receptor, modulate the 
GABA induced current and exert their effects by initiating an allosteric transition in 
the protein that indirectly modifies the conformation of the agonist binding site 
(Changeux and Edelstein 1998; Teissere and Czajkowski 2001). There can be 
compounds enhancing the GABA induced currents, such as benzodiazepines which 
exhibit anxioloytic, anticonvulsant, muscle relaxant, sedative and hypnotic effects, or 
compounds reducing the action of the receptor which exhibit anxiogenic and 
convulsant effects (Sieghart 1995). The large pharmacological variety of compounds 
can be ascribed to differing binding modes at the binding pocket. Furthermore, the 
expression of different GABAA receptor subunits in various brain regions, results in 
functionally different receptor subtypes (Sieghart 1995). Depending on their subunit 
composition the receptors show different pharmacological and electrophysiological 
properties (Sarto-Jackson and Sieghart 2008). 
 
1.5.Outline of the Project 
The following master thesis is integrated into the Neurocypres project of the 
European Union. It was the objective of my master thesis to investigate whether it is 
possible to engineer a benzodiazepine binding site by a consecutive introduction of 
point mutations into hetero-oligomeric α1β3 GABAA receptors (Fig. 1.4 C). For this, 
an α1β3 receptor (Fig. 1.4 B) was chosen as a model system, as it has, compared to 
an α1β3γ2 receptor (Fig. 1.4 A), no high affinity benzodiazepine binding site but still 
two GABA binding sites. These are important for the pharmacological 
characterization with benzodiazepines, as benzodiazepines cannot open the chloride 
channel but only modulate GABA-induced currents.  
This diploma thesis was the first step for demonstrating the feasibility of engineering 
a benzodiazepine binding site into a related receptor that does not contain such a site. 
Incorporation of such a site in receptors that can be crystallized, could then be used 
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as a starting point for first crystallization trials of this binding site and drug 
development studies. 
 
Figure 1.4: Schematic structure of the extracellular domain of GABAA receptor types 
(top down view). (A) The wild type α1β3γ2 receptor has a benzodiazepine binding site 
situated at the α-plus/γ-minus interface, (B) in the wild type α1β3 receptor a β replaces 
the γ subunit. This receptor exhibits no high affinity benzodiazepine binding site, (C) 
the engineered α1β3 receptor with the introduced benzodiazepine binding sites, with 
important amino acids of the γ-minus side introduced into the β-minus side. Arrows 
indicate the location of the GABA and the benzodiazepine binding site(s).  
To achieve the goal of this thesis we engineered important amino acid residues of the 
γ2-minus side of the α1β3γ2 receptor, into the β3-minus side of an α1β3 receptor as 
Fig. 1.4 (C) shows. The amino acid residues were selected by using a structural 
model of the diazepam-bound benzodiazepine binding site as a template that was 
recently developed (Richter submitted) and previously published mutagenesis data. 
A total of six different mutant β3pCI constructs were generated, co-expressed in 
different heterologous cell systems together with wild type α1 subunits, and 
investigated by biochemical, electrophysiological and radioligand binding 
techniques.  
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2. MATERIAL AND METHODS 
2.1. Generation of Mutated cDNA Constructs 
For the cloning of mutated β3 subunits, pCI expression vectors (Promega, 
Madison, Wisconsin) were used. Seven mutant constructs were designed by the 
method of “gene SOEing” PCR technique (Horton 1993) using a β3pCI vector as 
template, which had a the full length of a rat β3 subunit (1421bp) incorporated in a 
pCI vector (Ehya, Sarto et al. 2003). The mutant products replaced parts of the wild 
type sequence on the vector. The Escherichia Coli strain XL1-Blue (Stratagene, La 
Jolla, California) was used for plasmid amplification and isolation. Transformations 
were performed as published previously (Fuchs, Zezula et al. 1995). The wild type 
β3pCI vector, as well as the resulting mutant products, were digested with the 
restriction enzymes PstI and XhoI (Promega, Madison, Wisconsin) for subsequent 
ligation.  
 
2.1.1. Gene SOEing, PCR 
The Polymerase Chain Reaction (PCR) method of “gene SOEing” (Gene 
Splicing by Overlap Extension) was used to generate single mutations or chimeric 
constructs by the overlap extension of two complementary sequences using the PCR 
technique. With the technique of “gene SOEing”, synthetic oligonucleotide primers 
containing the recombinant sequence become incorporated into the final PCR 
product (Pogulis, Vallejo et al. 1996).  
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Figure 2.1: The method of Gene Splicing by Overlap Extension (Horton 1993) 
This method was described by Horton (Horton 1993). Recombinant primers, 
complementary to the open reading frame (ORF) of the β3 subunit within the 
template DNA were designed for nucleotide synthesis in 5’ to 3’ direction and 
contained a 3’priming region which binds to the β3pCI template DNA (with an 
annealing temperature of 60°C), and a 5’overlapping region (for the overlap of the 
two internal primers) containing the mutation/chimeric sequence. In addition, two 
flanking primers were chosen near the restriction sites PstI or XhoI. In two separate 
PCR reactions, flanking primers (a, d) and recombinant primers (b, c) generated two 
overlapping fragments AB, CD (Fig. 2.1), which were fused in a second round of 
PCR (Pogulis, Vallejo et al. 1996). In the second round of PCR the 3’upper strand of 
the AB fragment could hybridize with the 5’end of the lower strand of the fragment 
CD (with an annealing temperature at 56°C). High fidelity DNA polymerase 
(Hoffmann-La Roche, Basel, Swiss) proceeded to complete the mutant product, as 
the overlapping strands were themselves primers, resulting in a full-length mutant 
product AD (Horton 1993; Pogulis, Vallejo et al. 1996).  
 
2.1.2. Digestion and Purification of DNA  
After the generation of the mutant constructs, PCR products were purified 
using the GFX purification kit of DNA from agarose gel (GE Healthcare, Chalfont 
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St. Giles, Buckinghamshire). The eluates were digested with the restriction enzymes 
PstI and XhoI according to the manufacturer’s protocol (Promega, Madison, 
Wisconsin). Linear DNA fragments were purified from the solution containing the 
restriction enzymes, using the GFX purification kit for DNA. In parallel, wild type 
β3pCI vectors were digested with the respective restriction enzymes and purified 
from a preparative agarose gel using the GFX purification kit for DNA. 
 
2.1.3. Preparative Agarose Gel for Band Separation 
Preparative agarose gel for band separation by length was used to purify 
mutant PCR products and digested wild type β3pCI vectors. Agarose (Invitrogen, 
Carlsbad, California) gels (0.01g/ml) were prepared in 1xTBE (10xTBE: 890mM 
Tris, 890mM boric acid, 31mM EDTA) with the addition of ethidium bromide 
(stock: 10 mg/ml) to a final concentration of 0.5 µg/ml. Electrophoretic separation of 
DNA fragments was performed at 100V. 
 
2.1.4. GFX Purification of DNA from Gel 
DNA was purified with a GFX Purification Kit. Following electrophoresis of 
the DNA, the respective agarose band was excised from the gel and dissolved by the 
addition of capture buffer at 60°C. A GFX MicroSpin column was incubated with the 
solution and centrifuged. The column was washed with 500µl Tris-EDTA buffer 
(10mM Tris-HCl with pH 8.0, 1mM EDTA, 80% Ethanol) and centrifuged again. 
DNA was eluted with TE buffer (10 mM Tris-HCl with pH 8.0, 1mM EDTA). For a 
detailed protocol see website of GE Healthcare. 
 
2.1.5. GFX Purification of DNA from Solution 
To 100µl of the respective solution 500µl capture buffer was added. After 
transfer to the GFX MicroSpin column, sample was processed as described above.  
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2.1.6. Ligation of DNA Fragments 
Ligation of the linear DNA fragments and the linearized vectors was 
performed using the protocol of the Rapid DNA Ligation Kit (Hoffmann-La Roche, 
Basel, Swiss). Following the ligation of the mutated DNA fragments and the 
linearized wild type vector, XL1-Blue E.coli competent cells were transformed with 
the ligation mix.  
 
2.1.7. Chemically Competent XL1-Blue E.coli Cells 
- Generation 
30ml SOB medium (2% Bacto-Trypton, 0.5% Bacto-Yeast Extract, 10mM 
NaCl, 2.5mM KCl) was prepared with a tetracycline concentration of 12.5 µg/ml 
(stock 5 mg/ml). Frozen glycerol cultures of E.coli XL1-Blue bacterial cells were 
dissolved in the medium with an inoculating loop, and incubated for 16 hours at 37 
°C. Subsequently, a suspension culture was prepared with 60ml SOB adding 0.6ml 
Mg2+stock (10mM MgCl2, 10mM MgSO4) together with 0.5ml of the overnight 
culture, and grown at 37°C until reaching an optical density of 0.45 (OD600).  The 
culture was centrifuged at 1000xg, 15 min, 4°C, then resuspended in 12.5ml FSB 
(10mM KCH3COO, 100mM KCl, 45mM MnCl2, 10mM CaCl2, 3mM Cobalt 
hexamine trichloride, 10% Glycerol, with pH of 7.0, sterile filtered), incubated on ice 
for 15 min. and centrifuged again at 1000xg, 15 min, 4°C.  The pellet was 
resuspended in 3.8ml FSB together with 140µl DMSO, following a second addition 
of 140µl DMSO after 5min. Finally the cell suspension was aliquoted and stored at -
70°C. 
- Transformation 
Aliquots of 200µl of frozen competent XL1-Blue bacterial cells were thawed on 
ice for 10min. About 1ng of the ligated plasmid DNA was added to the competent 
cells and incubated for 30min. After a heat shock of 90sec. at 42°C, and an 
incubation on ice for 2min., 800µl of SOC medium (SOB, plus 10µl/ml 2M Glucose) 
were added and the mixture was incubated for 1hour at 37°C. Finally the transformed 
cells were plated on a LB/Amp-agar plates (1% Bacto-Trypton, 0.5% Bacto-Yeast 
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Extract, 85mM NaCl, 1.5% Agar, adding 100 µg/ml ampicilin). As a control, the 
wild type β3pCI plasmid was transformed and plated in parallel to the mutant 
plasmids. 
 
2.1.8. Screening for Recombinant Clones  
In order to confirm successful ligation and transformation of the mutant or 
chimeric plasmids, a PCR screen was performed. For this, several colonies were 
picked from the LB/Amp agar plate and resuspended in 100µl TE buffer. From this, 
40µl of cell suspension were transferred into 1ml LB/Amp solution (1% Bacto-
Trypton, 0.5% Bacto-Yeast Extract, 85mM NaCl, adding 100 µg/ml ampicillin) and 
grown at 37°C. The remaining cell suspension in the TE buffer was subjected to a 
heat shock for 5min at 95°C, was incubated on ice and centrifuged at 1600xg, 2min. 
The supernatant was used for the PCR screen with the standard protocol of using Taq 
DNA polymerase (Qiagen, Valencia, California). After PCR, two positive clones 
were selected and grown in LB/Amp solution for 16hours.  
 
2.1.9. Purification of DNA with the Mini-Kit from QIAgen 
The DNA was prepared using the QIAgen Plasmid Mini-Kit according to the 
manufacturer´s protocol (Qiagen, Valencia, California). DNA concentrations were 
calculated by measuring the photometric absorption at 260nm.  DNA samples 
containing the appropriate mutations were verified by sequencing.  
 
2.1.10. Generation of Glycerolstocks 
Storage of transformed bacterial cultures was prepared by the addition of a 
glycerol freezing solution (gylcerol) to the fresh grown cultures in a 1:1 ratio, and 
frozen at -70°C. 
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2.1.11. Purification of DNA with the Maxi-Kit from QIAgen 
Following the confirmed introduction of mutations into the β3pCI vectors, 
positive clones were grown for 16hours in LB/Amp solution and then purified 
according to the protocol of Qiagen Plasmid Maxi-Kit (Qiagen, Valencia, 
California). 
 
2.2. Transfection of HEK 293 Cells 
Transformed Human Embryonic Kidney cells (HEK 293) were cultured as 
described before (Tretter, Ehya et al. 1997). HEK cells were grown in DMEM 
medium (Gibco, Carlsbad, California) with 1x MEM non essential amino acids 
(Gibco, Carlsbad, California), 10% fetal calf serum (BioWhittaker, Walkersville, 
Maryland), 2mM L-Glutamine, 100U/ml penicillin G sodium and 100µg/ml 
streptomycin sulfate added additionally. Cells were grown in the incubator at 
37°C/5% CO2 until reaching a cell number of 2 x 106 per plate. With a total of about 
20µg cDNA/per plate, HEK cells were co-transfected with wild type α1 together 
with wild type β3, γ2 or mutated β3 subunits in a ratio of 1:1:1, as described 
previously (Sarto-Jackson, Furtmueller et al. 2007). The transfection was performed 
using the calcium phosphate precipitation method (Chen and Okayama 1988). A 
glycerol shock was performed to increase the rate of transfection. Cells were 
harvested after 48 hours of growth, in order to allow receptor expression.  
 
2.3. Antibodies 
The antibodies α1(1-9), or β3(1-13) or β3(345-408) were generated in rabbits 
recognizing the epitopes according to amino acids sequences 1-9 of the mature α1 
subunit or 1-13 or 345-408 of the mature β3 subunit, respectively. The antibodies 
were affinity purified as described previously (Tretter, Ehya et al. 1997; Jechlinger, 
Pelz et al. 1998). All antibodies were tested for their specificity and lack of cross-
reactivity (previous experiments, not shown). 
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2.4. Immunoprecipitation of Receptors Expressed at the Cell Surface 
The medium of transfected HEK cells was removed from the culture dishes. Cells 
were washed once in 1x Phosphate Buffered Saline (PBS: 4.3mM Na2HPO4, 2.7mM 
KCl, 140mM NaCl, 1.5mM KH2PO4, with a pH 7.3) and incubated for 5min. with 
5mM EDTA/PBS to detach cells from dishes. DMEM was added and the cell 
suspension was centrifuged at 1000xg for 5min at 4°C. The pellet was resuspended 
in DMEM and the cell suspension of three plates was incubated with either 35µg of 
an α1(1-9) or β3(1-13) antibody, both directed against the N-terminal region of the 
respective subunits. Incubation was performed for 45 min. at 37°C to specifically 
label GABAA receptors expressed at the cell surface. Following incubation, cells 
were repeatedly centrifuged and washed in PBS to remove unbound antibody. With 
an IP-Low solution (50mM Tris-HCl, 150mM NaCl, 1mM EDTA pH 8.0, 0.5% 
Triton X-100) containing the detergent TritonX-100, proteins were extracted by 
shaking for 1 hour. Following a centrifugation step at 150.000xg at 4°C for 20min, 
the supernatant containing the proteins was collected. Immunoprecipitin (Invitrogen, 
Carlsbad, California) was prepared as described previously (Tretter, Ehya et al. 
1997), diluted together with 5% milk powder in IP-low buffer and added to the 
supernatant shaking for 2 hours at 4°C, in order to precipitate the bound antibodies. 
The precipitate was centrifuged at 10.000xg for 5min at 4°C and the supernatant of 
the precipitated proteins was dissolved in NuPAGE sample buffer (Invitrogen, 
Carlsbad, California) for subsequent SDS-PAGE and Western blot analysis. It was 
previously shown that under these conditions the redistribution of antibodies could 
be excluded (Klausberger, Fuchs et al. 2000). 
 
2.5. SDS-PAGE and Western Blot Analysis 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) is a 
method where proteins are denaturated by the detergent SDS, and separated 
according to their molecular mass in a polyacrylamid matrix (Neville and Glossmann 
1974). A 10% separating gel (25% separating gel buffer containing 1.5M Bis-Tris at 
a pH 6.4, 30% acrylamid whereof is 0.8% N, N’-methylen-bis-acrylamid, 10% SDS, 
1% Tetraethylmethylendiamin (TEMED), 10% APS) was prepared in a NOVEX gel 
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cassette (Invitrogen, Carlsbad, California). A 5% stacking gel (25% stacking gel 
buffer containing 0.5M  Bis-Tris at a pH 6.4, 30% acrylamid whereof is 0.8% N, N’-
methylen-bis-acrylamid, 10% SDS, 1% Tetraethylmethylendiamin (TEMED), 10% 
APS) was casted over the separating gel, concentrating the proteins into a thin 
starting zone for subsequent electrophoresis. After polymerization, the gel cassette 
was placed into the running chamber and samples of previous immunoprecipitation 
experiments were loaded onto the gel together with 1µg/µl of prestained MagicMark 
XP Western Standard and an unstained SeaBlue2 marker (both Invitrogen, Carlsbad, 
California). The outer chamber was filled with 1x MOPS (20x stock: 1M MOPS, 1M 
Tris, 20mM EDTA, 2% SDS), while the inner chamber was filled with 1x MOPS 
adding 0.25% NuPAGE antioxidant (Invitrogen, Carlsbad, California). The gel ran 
for 45min. at 200V, 125mA. After the electrophoresis was completed, the gel 
cassette was cracked open, and washed in 1x transfer buffer (10x stock: 479mM Tris, 
386mM Glycine, 0.5% SDS). In parallel, a PVDF (polyvinylidene fluoride) 
Immobilon-P membrane (Milipore, Billerica, Massachusetts) was washed first in 
methanol, then ddH2O and finally in 1x transfer buffer. The blotting sandwich was 
built as follows: filter paper (Whatman, Atlanta, Georgia) pre-wetted in 1x transfer 
buffer – PVDF Immobilon-P membrane – the SDS-PAGE gel – pre-wetted filter 
paper, and was blotted for 60min at 20V, 58mA (per Gel). Afterwards the membrane 
was washed with blocking buffer (1.5% milk powder, 0.1% Tween-20) and 
incubated with digoxigenin labeled α1(1-9) or β3(345-408) antibodies, shaking for 
16 hours at 4°C. Membranes were then washed repeatedly with blocking buffer, and 
incubated at room temperature with secondary anti-digoxigenin, alkaline phosphatase 
coupled antibodies for subsequent chemiluminescence detection (Roche, Mannheim, 
Germany). Following incubation, the membrane was washed repeatedly in blocking 
buffer and subsequently in assay buffer (1mM MgCl2, 25mM dietholamine at a pH 
10.0). For visualization, the substrate of the alkaline phosphatase CDP-Star (Applied 
Biosystems, Bedford, Massachusetts) was added and analyzed by the Fluor-S 
Multimager (X-OMAT UV, Kodak). As shown previously, the bands of the α1 
subunits appeared at 50kDa, while β3 subunits between 50-55kDa (Tretter, Ehya et 
al. 1997). 
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2.6. Chemicals 
Compounds were purchased from the following sources: [N-Methyl-3H]Ro15-
1788 (87.0 Ci/mmol) (Perkin-Elmer Life Sciences, Wellesley, Massachusetts), 
diazepam (7-chloro-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one), 
flurazepam (7-Chloro-1-(diethylamino)ethyl-5-(2-fluorophenyl)-3H-1,4-
benzodiazepin-2(1H)-one dihydrochloride) (Sigma Aldrich, St. Louis, Missouri), 
Ro15-1788 (ethyl-8-fluoro-5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-
a][1,4]benzodiazepine-3-carboxylate) (Tocris Bioscience, Bristol, UK). 
 
2.7. Two Electrode Voltage Clamp 
Mature female Xenopus laevis (Nasco, Fort Atkinson, Wisconsin) were 
anaesthetized (0.17 % Tricaine, Sigma Aldrich, St. Louis, Missouri), decapitated and 
their ovary was removed. Xenopus laevis oocytes were prepared as described 
previously (Sigel, Baur et al. 1990). Stage 5 to 6 oocytes with the follicle cell layer 
were singled out of the ovary using a platinum wire loop. Cells were then injected 
with 3ng cDNA solution endocing for wild type or recombinant α1and β3 subunits 
(ratio 1:1), or α1, β3, and γ2 subunits (ratio 1:1:5), and incubated at +18°C in Bath 
Solution (10mM Hepes, pH 7.4, 88mM NaCl, 1mM KCl, 2.4mM NaHCO3, 0.82mM 
MgSO4, 0.34 Ca(NO3)2, 0.41mM CaCl2 and 100 units/ml penicillin, 100µg/ml 
streptomycin). After at least 36 hours (depending on the subunit composition), cells 
were defolliculated with collagenase IA (Sigma Aldrich, St. Louis, Missouri) and 
trypsin inhibitor Type I-S from soybean (Sigma Aldrich, St. Louis, Missouri) and 
incubated in Xenopus ringer solution (5mM Hepes, pH 7.4, 90mM NaCl, 1mM 
MgCl2, 1mM KCl, 1mM CaCl2) for another 24 hours. Two electrode voltage clamp 
measurements were performed at a holding potential of -60mV using electrodes with 
a resistance between 1-4MΩ . Xenopus Ringer solution was used as perfusion buffer, 
and 2M KCl as inner electrode solution. Compounds were measured at a GABA 
concentration eliciting 3-5% maximal GABA current. The compounds flurazepam 
and Ro15-1788 were investigated in detail. Both are benzodiazepines which are 
known to bind with high affinity at the α-plus/γ-minus interface of the GABAA 
receptor. Between the applications of the different compounds, the perfusion system 
was washed with DMSO. The percentage of modulation of the GABA currents was 
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compared to GABA control currents. All data analysis was performed using 
GraphPad Prism 4 program (GraphPad Software Inc., San Diego, California). 
 
2.8. Receptor Binding Studies 
The experimental procedure was adapted from previously described protocols 
(Ogris, Poltl et al. 2004; Sarto-Jackson, Furtmueller et al. 2007). Frozen membranes 
of transfected HEK cells were thawed and solubilized in TC50 buffer (50mM Tris, 
15.5mM Citric acid at pH 7.4). Membranes were homogenized by Ultra-Turrax and 
centrifuged at 150000xg at 4°C for 20 minutes. After resuspension in TC50 they 
were repeatedly ultra-turraxed and kept on ice. Protein concentrations were measured 
with a BCA Protein Assay kit (Thermo Fisher Scientific Inc., Rockford, Illinois) and 
compared to a bovine serum albumin (BSA) standard curve generated in parallel 
ranging from 100-1000µg/µl. For the binding assay, membranes were incubated for 
90 min. at 4°C in a 1ml solution, containing TC50 buffer, 150mM NaCl and different 
concentrations of [3H]Ro15-1788 (87Ci/mmol, DuPont, Boston, Massachusetts) 
ranging from 0.1-20nM, in the presence or absence of 100µM diazepam or Ro15-
1788. Whatman GF/B filters (Whatman, Maidstone, Kent) were pre-wetted with ice 
cold water, the incubated membrane samples were filtered through and then rinsed 
with 3.7ml of ice cold TC50. Filters were then dissolved in the liquid scintillation 
cocktail Ultima Gold (Perkin Elmer, Wellesley, Massachusetts) and placed into the 
liquid scintillation counter over night. All data analysis was performed using 
GraphPad Prism 4 program (GraphPad Software Inc., San Diego, California). The 
respective maximal number of binding sites of the specific ligand per mg/protein 
(Bmax) and the dissociation constant (KD) describing the affinity of wild type and 
recombinant receptors were determined. The experiment was repeated once (α1β3γ2 
wild type receptors) or thrice (α1β3DGE recombinant receptors) using cell 
membranes from different transfections. 
For the inhibition studies, membranes were incubated with [3H]Ro15-1788 in the 
range of the KD of the respective receptors, which were determined in previous 
receptor binding studies. Membranes of wild type α1β3γ2 were incubated with 
10nM, and α1β3DGE recombinant receptors with 30nM of tritium labeled [3H]Ro15-
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1788 together with TC50 buffer, 150mM NaCl, different concentrations of unlabeled 
flurazepam (3nM– 30µM), in a total volume of 1ml for 90min. at 4°C. Nonspecific 
binding was determined in the presence of 100µM Ro15-1788 and subtracted from 
total [3H]Ro15-1788 binding, in order to obtain specific binding. Samples were 
filtered and analyzed as described above.  
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3. RESULTS 
3.1. Generation of Mutated β3 Subunits 
Amino acids of the minus side of the γ2 subunit, which have previously been 
demonstrated to be important for benzodiazepine binding (Sigel and Buhr 1997; 
Wingrove, Thompson et al. 1997; Kucken, Wagner et al. 2000; Ernst, Brauchart et al. 
2003; Kucken, Teissere et al. 2003; Ernst, Bruckner et al. 2005; Richter submitted) 
were introduced into the minus side of a β3 subunit (Fig. 3.1), using a pCI plasmid 
containing the full length of a rat β3 subunit as a template. The selection of amino 
acids was based on predictions from modelling studies (Ernst, Brauchart et al. 2003; 
Ernst, Bruckner et al. 2005; Richter submitted) and on published mutagenesis data. 
All mutations introduced, together with their positions on the “loops” are 
summarized in Fig 3.1 (B). Of these so-called “loops” only three are loops in the 
structural sense (Elliott 2003), because the six segments that form the binding pocket 
were identified prior to their 3D structure. The other three turned out to be pieces of 
beta strand (Ernst, Brauchart et al. 2003; Ernst, Bruckner et al. 2005). For the full 
length sequence alignment of the β3 together with the γ2 subunit see the appendix. 
 
Fig. 3.1: (A) Model structure of GABAA receptor extracellular domains of an α1β3 
receptor. The α-plus/β-minus interface is viewed from the side. (B) Positions of the 
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introduced mutations on the respective “loops” (D, G, E, F) of the β-minus pocket 
lining interface indicated with green arrows (modified after Ernst, 2009, unpublished). 
In „loop“ D two amino acid residues of the γ2 minus side were incorporated into the 
β3 minus side. The first amino acid which was chosen for our studies was the residue 
γ2F77, identified as a key determinant of the benzodiazepine binding (Buhr, Baur et 
al. 1997; Wingrove, Thompson et al. 1997; Sigel, Schaerer et al. 1998) replacing the 
homologous β3Y62. The second residue mutated in our studies was the amino acid 
γ2A79 (Kucken, Wagner et al. 2000) replacing the homologous β3Q64. It was shown 
that longer amino acid side chains would cause a decrease in binding affinities of 
benzodiazepines (Kucken, Teissere et al. 2003). Both residues are located adjacent to 
each other on a β-strand and are presumably pocket lining residues. Subsequently, 
the amino acid γ2Y58 (Buhr, Baur et al. 1997; Kucken, Wagner et al. 2000) of 
„loop“ G was introduced in the β3 subunit, replacing β3D43 at the homologous 
position. This residue was chosen due the observation, that all γ subunits of the 
GABAA receptor have a tyrosine (Y) and all β subunits have an aspartic acid (D) at 
the homologous amino acid residue position. In „loop“ E the amino acid γ2T142, 
neighbouring the γ2F77 residue in the anti-parallel sheet, was shown to be important 
for high affinity benzodiazepine binding (Pritchett, Sontheimer et al. 1989; Mihic, 
Whiting et al. 1994; Wingrove, Thompson et al. 1997), and therefore replaced the 
β3G127. In 2007, Sancar et al. published an amino acid stretch in „loop“ F of the γ2 
subunit, required for binding of the imidazopyridine zolpidem, which is structurally 
different from classical benzodiazepines (Sancar, Ericksen et al. 2007; Hanson, 
Morlock et al. 2008). As the residues of „loop“ F are not well defined, two different 
chimeras were designed for our studies. For this, we substituted either a longer 
sequence (amino acids γ2(186-197)) or a shorter sequence (amino acids γ2(186-192)) 
for the homologous amino acid residues of the β3 subunit. 
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Figure 3.2: Table of mutated β3pCI constructs in „loops“ G, D, E and F. Mutations 
were subsequently introduced: construct β3D1pCI carries the mutation Y62F, 
β3D2pCI the mutations Y62F and Q64A, β3DGpCI the mutations Y62F, Q64A and 
D43Y, β3DGEpCI the mutations Y62F, Q64A, D43Y and G127T, β3DGE-F7pCI the 
mutations Y62F, Q64A, D43Y, G127T and a shorter sequence (amino acids γ2(186-
192)), and β3DGE-F12pCI the mutations Y62F, Q64A, D43Y, G127T and a longer 
sequence (amino acids γ2(186-197)) of the β3 subunit with the homologous amino acid 
residues of the γ2 subunit. 
Thus, a total of six different mutated β3pCI constructs were generated (Fig.3.2). The 
first construct β3D1pCI carries the mutation Y62F. Here, the amino acid residue 
Tyrosine (Y) at the position 62 (of the mature peptide) in the β3 subunit was changed 
to the homologous amino acid residue Phenylalanine (F) of the γ2 subunit. Construct 
β3D2pCI carries the mutations Y62F and Q64A, β3DGpCI the mutations Y62F, 
Q64A and D43Y, β3DGEpCI the mutations Y62F, Q64A, D43Y and G127T, 
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β3DGE-F7pCI the mutations Y62F, Q64A, D43Y, G127T and a chimeric sequence 
containing the seven amino acids γ2(186-192), and β3DGE-F12pCI the mutations 
Y62F, Q64A, D43Y, G127T and a chimeric sequence containing the twelve amino 
acids γ2(186-197).  
Wild-type or mutated β3 subunits were then co-expressed together with a wild type 
α1 subunit, to form a functional pentameric α1β3 GABAA receptor (Baumann, Baur 
et al. 2001).  
 
3.2. Surface Precipitation Indicates a Comparable Expression and Assembly of 
Wild Type and Mutated α1β3 GABAA Receptors 
To investigate the level of expression and assembly of mutated β3 subunit 
constructs, receptors on the cell surface expressed in HEK cells were investigated by 
the method of cell surface precipitation. HEK cells were co-transfected with wild-
type α1 together with wild-type or mutated β3 receptors. Receptors at the cell surface 
were labeled with β3(1-13) (Fig. 3.3 A) or α1(1-9) antibodies (Fig. 3.3 B). Labeled 
receptors were extracted and precipitated by the addition of Immunoprecipitin. SDS-
PAGE and Western blot analysis was performed using digoxigenin labeled β3(345-
408) or α1(1-9) antibodies.  
 
Fig. 3.3: (A) Cell surface expression of GABAA receptors containing wild-type α1 and 
β3 or mutated β3 subunits. HEK cells were co-transfected with α1 and β3, β3D1, β3D2, 
β3DG, β3DGE, β3DGE-F12 or β3DGE-F7 subunits. GABAA receptors expressed at the 
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surface were immunolabeled by an incubation of intact cells with β3(1-13) antibody. 
Receptors were then extracted, precipitated by Immunoprecipitin, and subjected to 
SDS-PAGE and Western blot analysis using digoxigenin-labeled α1(1-9) or β3(345-408) 
antibodies. The complete experiment was performed once. (B) Cell surface expression 
of GABAA receptors containing wild type α1, β3 or α1, β3 and γ2 subunits. GABAA 
receptors expressed at the surface were immunolabeled by α1(1-9) antibody and 
Western blot analysis was performed using digoxigenin-labeled α1(1-9) antibody.  
Recombinant α1β3D1, α1β3D2, α1β3DGE receptors showed a comparable expression 
to the wild type α1β3 receptors when precipitated with β3(1-13) antibodies and 
detected with α1(1-9) digoxigenin labeled antibody (protein band at 50kDa) and with 
β3(345-408) digoxigenin labeled antibody (protein band at 50-55kDa) (Fig.3.3 A). 
There is evidence, that in addition to α1β3 receptors, β3 homopentameric receptors 
are present in transfections (Tretter, Ehya et al. 1997). Recombinant receptors 
composed of α1 and β3DG subunits, seemed to exhibit a lower degree of β3 
homopentameric receptors, because there is a comparable expression of α1 subunits, 
but a reduced expression of β3 subunits. The increased staining of α1β3D2 receptors 
when detected with β3(345-408) digoxigenin labelled antibody could indicate the 
additional expression of β3 homopentamers. To confirm these assumptions, the 
experiments would have to be repeated. Recombinant receptors α1β3DGE-F12 and 
α1β3DGE-F7 showed a dramatically decreased expression on the cell surface, 
suggesting that subunit assembly or receptor formation in α1β3DGE-F12 and 
α1β3DGE-F7 receptors is interrupted to some extent, as similar results were obtained 
when precipitation of total receptors was performed (results not shown). As shown in 
Fig.3.3 B and previous experiments, there is no significant difference in expression at 
the cell surface between wild type α1β3γ2 and α1β3 receptors (Sarto-Jackson, 
unpublished data). 
 
3.3. Electrophysiological Investigation of Recombinant Receptors α1β3DG and 
α1β3DGE with Flurazepam and Ro15-1788 (Flumazenil) 
Functional investigations were performed with wild type α1β3, α1β3γ2 and 
recombinant α1β3DG, α1β3DGE receptors using two electrode voltage clamp 
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electrophysiology. For that, Xenopus laevis oocytes were co-injected with cDNA of 
wild type α1 and β3DG or β3DGE subunits into the cell nucleus. Two days after 
injection GABA elicited currents were recorded at a holding potential of -60mV. 
First GABA-dose-response curves were measured. Then compound dose-response 
curves were measured at a GABA concentration eliciting 2-5% of the maximal 
GABA current. Recombinant receptors α1β3DG and α1β3DGE were characterized in 
detail with the compounds flurazepam (Fig. 3.5) and Ro15-1788 (Fig. 3.6). Their 
chemical structure is shown in Fig.3.4 below. 
 
Fig.3.4: Chemical structure of investigated benzodiazepines. The core chemical 
structure is a benzene ring fused with a diazepine ring. (A) Flurazepam, containing a 
diethylamino nitrogen side chain on N1. (B) Ro15-1788, has an imidazo-ring together 
with an ester group as side chain. 
The concentration-effect curve of flurazepam for the respective receptors is shown in 
Fig. 3.5 (A-C). In the compound dose-response curve (Fig. 3.5 D) the percentage of 
the modulation of GABA currents is plotted against increasing concentrations of the 
respective compound. Compounds were dissolved in DMSO to maximum solubility 
and were then adequately diluted to result in a maximum of 0,1% of DMSO in the 
final superfusion solution.  
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Figure 3.5:  Concentration-effect curve of flurazepam for (A) α1β3γ2, (B) α1β3 and (C) 
α1β3DGE receptors. (D) Xenopus laevis oocytes were injected with cDNA and 
investigated by the two electrode voltage clamp method. Modulation of GABA currents 
in recombinant α1β3γ2 (■, n=10), α1β3 (●, n=8), α1β3DG ( ▲, n=7) and α1β3DGE (×, 
n=8) receptors by flurazepam.  
GABA-elicited currents of flurazepam (1nM to 800µM) were recorded. As shown 
before (Walters, Hadley et al. 2000), flurazepam exerts two effects on α1β3γ2 wild 
type receptors (Fig 3.5 A). The first effect, the positive modulation of the GABA 
currents up to the concentration of 25µM is exerted via the benzodiazepine binding 
site, which is located at the α-plus/γ-minus interface. In this concentration range 
flurazepam has no modulatory effect on α1β3 receptors (Fig. 3.5 B). At higher 
concentrations (starting from 25µM) a second negative modulatory effect occurs at 
both wild type α1β3 and α1β3γ2 receptors (Fig. 3.5 A, B), which was shown to be 
exerted through a binding site located at the α-plus/β-minus interface (Baur, Tan et 
al. 2008). When applied to the recombinant mutated receptors α1β3DG (not shown) 
and α1β3DGE (Fig. 3.5 C), flurazepam positively modulates GABA currents, which 
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is in contrast to α1β3 receptors. The positive modulation of GABA currents in both 
recombinant receptors is significant compared to α1β3 receptors starting from 10µM 
flurazepam (p<0.005), while the difference in modulation between α1β3DG and 
α1β3DGE receptors is not significant (p>0.05). These results demonstrate that the 
α1β3 character of recombinant receptors was changed towards an α1β3γ2 receptor by 
the introduction of the respective mutations. At higher concentrations ranging from 
25µM up to 500µM, both mutated receptors exert a strong positive modulation, 
whereas a decrease in positive modulation is induced only at concentrations at 
800µM. Compared to α1β3γ2 wild-type receptors, not only the compound dose-
response curve, but also the negative modulatory effect on GABA current 
potentiation at high concentrations, seems to be reduced and shifted to the right (Fig. 
3.5 D). In Fig. 3.5 (C) a complete concentration-effect curve of α1β3DGE 
demonstrates this effect.  
The effects of Ro15-1788 (1nM to 100µM) on GABA-elicited currents were 
recorded in wild type α1β3γ2 (Fig 3.6 A), α1β3 (Fig 3.6 B) receptors, or recombinant 
α1β3DG (not shown), and α1β3DGE (Fig 3.6 C) receptors. 
 
Figure 3.6:  Concentration-effect curve of Ro15-1788 for (A) α1β3γ2, (B) α1β3 and (C) 
α1β3DGE receptors. Xenopus laevis oocytes were injected with the respective cDNAs 
34 
 
and investigated by the two electrode voltage clamp method. (D) Modulation of GABA 
currents in recombinant α1β3γ2 (■, n=4), α1β3 (●, n=2), α1β3DG ( ▲, n=4) and 
α1β3DGE (×, n=6) receptors by Ro15-1788.  
It has been shown before (Hunkeler, Mohler et al. 1981; Walters, Hadley et al. 2000) 
that Ro15-1788 is a selective antagonist for the high-affinity benzodiazepine binding 
site at GABAA receptors and therefore shows no significant positive modulatory 
effect on wild-type receptors (Fig 3.6 A, B). Interestingly the two recombinant 
receptors α1β3DG and α1β3DGE exert allosteric effects different from those of the 
wild type receptors. At both recombinant receptors Ro15-1788 positively modulates 
GABA currents, as the exemplary concentration-effect curve for α1β3DGE 
demonstrates (Fig. 3.6 C). The recombinant receptors α1β3DGE show already a 
significant onset potentiation of GABA currents at 10nM (p<0.005) Ro15-1788, 
compared to α1β3DG at 1µM (p<0.005) Ro15-1788 (Fig. 3.6 D). The dose-response 
curve of Ro15-1788 at α1β3DGE receptors reaches a plateau of saturation between 
1µM-10µM of Ro15-1788 (3.6 D), and slightly enhances the GABA current between 
10µM-100µM. The positive modulation of GABA currents by Ro15-1788 in 
α1β3DG recombinant receptors is much stronger than in α1β3DGE receptors.  
 
3.4. Binding of [3H]Ro15-1788 to HEK Cell Membranes Containing 
Recombinant α1β3DGE Receptors 
Because of the highly promising electrophysiological results obtained with 
recombinant α1β3DGE receptors, suggesting the introduction of a high affinity 
binding site (significant potentiation of GABA current at 10nM (p<0.005), half 
maximal potentiation at about 100nM for Ro15-1788), we were interested in 
determining the affinity of the benzodiazepine-like binding site, which was 
introduced by four mutations at the minus interface of the β3 subunit. For this, 
membranes of HEK cells, co-transfected with wild-type α1, β3, and γ2 (Fig. 3.7 A) 
or α1 and β3DGE (Fig. 3.7 B) subunits were incubated with different concentrations 
of [3H]Ro15-1788 ranging from 0.1nM to 20nM in the absence or presence of 
100µM diazepam or Ro15-1788. The affinity of the radioactive ligand [3H]Ro15-
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1788 for wild type and recombinant receptors (KD), and their respective binding site 
density (Bmax) was determined by Scatchard-analysis (graphs not shown). 
 
Figure 3.7: Saturation assay of [3H]Ro15-1788 binding in HEK cell membranes of (A) 
wild type α1β3γ2 (■) and (B) rec ombinant α1β3DGE (×) receptors. Membranes were 
incubated with increasing concentrations of [3H]Ro15-1788 (0,1-20nM) in the absence 
or presence of 100µM diazepam or Ro15-1788. Membranes were filtered through 
Whatman GF/B filters and specifically bound radioactivity was measured. Data are 
presented as mean ± S.D. of one experiment performed in triplicates. Experiments were 
performed once (A) or three times (B) with comparable results. Bmax gives the maximal 
number of binding sites of the specific ligand per mg/protein. KD gives the 
concentration at which 50% of the receptor is occupied by the ligand.  
Graph Pad Prism analysis of saturation assays revealed, that recombinant α1β3DGE 
receptors exhibit a KD of 64±22 nM (Fig. 3.7 B), compared to wild type α1β3γ2 
receptors which exhibit a KD of 3.7±0.5 nM (Fig. 3.7 A). KD values of recombinant 
α1β3DGE receptors, determined in two other experiments were 14±5 nM and 42±21 
nM (mean±SD, results not shown). This indicates the presence of a high affinity 
benzodiazepine binding pocket, although recombinant receptors exert an affinity 
twenty times lower than wild type α1β3γ2 receptors. The binding site densities 
differed significantly, as α1β3γ2 receptors had a Bmax of 10.280±462 fmoles/mg (Fig. 
3.7 A) and α1β3DGE receptors a Bmax of 807±266 fmoles/mg (Fig. 3.7 B), which 
suggests a mutated receptor formation of 7.5% in transfected HEK cells. In 
additional experiments recombinant α1β3DGE receptors exhibited Bmax values of 
232±50 fmoles/mg and 159±21 fmoles/mg (results not shown). The variability of 
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Bmax values in these experiments probably was due to different transfection 
efficiencies in different experiments.  
 
3.5. Inhibition of [3H]Ro15-1788 Binding by Flurazepam in HEK Cell 
Membranes of Recombinant α1β3DGE Receptors 
To further characterize the benzodiazepine binding site of recombinant α1β3DGE 
receptors, competition assays were performed. The potency of flurazepam for the 
inhibition of [3H]Ro15-1788 binding was determined. For that, membranes of HEK 
cells were co-transfected with wild-type α1, β3, and γ2 or α1 and β3DGE subunits 
and were incubated with 10nM or 30nM [3H]Ro15-1788 in the absence or presence 
of flurazepam concentrations, ranging from 3nM to 30µM (Fig. 3.8). The 
equilibrium dissociation constant (Ki) of the unlabeled ligand was calculated by the 
Cheng-Prusoff equation: Ki = IC50 / 1+ L/Kd (IC50… concentration of the unlabeled 
ligand, inhibiting the binding of the radioactive ligand by 50%; L…concentration of 
radioactive ligand; Kd… affinity of radioactive ligand to the receptor).  
 
Figure 3.8: Potency of flurazepam for inhibition of [3H]Ro15-1788 binding in HEK cell 
membranes of recombinant α1β3γ2 (■) and α1β3DGE ( ×) receptors. Membranes were 
incubated with 10nM or 30nM [3H]Ro15-1788 in the presence of 3nM to 30μM 
flurazepam. Membranes were filtered through Whatman GF/B filters and specifically 
bound radioactivity was measured. Data are presented as means ± S.D. of one 
experiment performed in triplicates and were fitted by GraphPad Prism using the 
equation for one site binding.  
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Recombinant receptors α1β3DGE exhibited a Ki of 7.1µM, compared to α1β3γ2 wild 
type receptors which exhibited a Ki of 75nM (Fig. 3.8). This hundredfold shift 
suggests a reduced potency of flurazepam for the inhibition of [3H]Ro15-1788.  
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4. DISCUSSION 
Despite the extensive clinical use of benzodiazepines, the molecular basis of their 
interaction with the GABAA receptor, as well as the protein structure of the 
benzodiazepine binding site is not known. Recently, modelling and docking studies 
of our group provided the first information on a possible structure of the diazepam 
bound benzodiazepine binding site (Richter submitted). This structural model is 
supported by all experimental data available and allows structural predictions of 
amino acid residues important for benzodiazepine binding. In the present work, it 
was used for predicting which amino acid residues present at the minus side of the γ2 
subunit have to be incorporated into the minus side of the β3 subunit of α1β3 
GABAA receptors, to engineer a high affinity benzodiazepine binding site, that is 
usually formed at the α1-plus/γ2-minus interface.  
 
4.1. The Diazepam-Bound Model of the GABAA Receptor Predicts Amino Acid 
Residues Important for Benzodiazepine Binding  
Flurazepam is a positive modulator at the benzodiazepine binding site formed by 
the α1-plus/γ2-minus interface, and interacts with lower potency at the α1-plus/β3-
minus interface causing no or a slightly negative modulatory activity (Baur, Tan et 
al. 2008). Together, these effects cause its biphasic modulatory action in α1β3γ2 
receptors (Fig. 3.5 A). In contrast, Ro15-1788 does not bind to the α1-plus/β3-minus 
interface. When flurazepam and Ro15-1788 were superposed with the α1-plus/β3-
minus interface it was shown that the compounds were able to exhibit an interaction 
similar to that at the α1-plus/γ2-minus interface with regard to the α1-plus side. 
However, several amino acid residues on the β3-minus side interfered with binding 
of Ro15-1788 and flurazepam. Thus, the amino acid residue β3Q64 on “loop” D 
clashed with the ester group of Ro15-1788. This explained the absence of a binding 
of this compound in the α1-plus/β3-minus pocket. In the case of flurazepam, the 
aromatic ring of β3Y62 on “loop” D exhibited a rotation different from that of γ2F77 
on “loop” D, due to the interference of its hydroxyl group with the pending phenyl 
ring of flurazepam. In addition, the charged residue β3D43 on “loop” G exhibited 
unfavourable interactions with the pending phenyl ring, overall explaining the 
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drastically reduced potency and altered efficacy of flurazepam (Fig. 3.5 D). It thus 
seemed clear that the respective residues of the β3 subunit had to be replaced by the 
homologous residues of the γ2 subunit. This was done in the present study by 
generating the construct β3DGpCI. 
In addition, the structural model predicted that β3G127 on “loop” E, could not 
form the H-bridge with the imidazo group of Ro15-1788. It was thus hypothesized 
that the introduction of an additional mutation into the β3 subunit converting the 
β3G127 to a threonine should increase the affinity and potency of Ro15-1788. 
Therefore the construct β3DGEpCI was generated that contained the first three 
mutations on loops D and G as in β3DGpCI, as well as the fourth mutation 
β3G127T.  
 
Fig.4.1: Flurazepam bound model of the β3 subunit minus site, with the engineered 
benzodiazepine pocket lining interface of the α1β3DGE recombinant receptor. 
Flurazepam is shown in ball-and-stick representation, with light-blue C-C bonds, H 
atoms in white, O atoms in red, N-atoms in blue, F atoms in green. The protein is 
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shown in ribbon mode with red for the β3 subunit. Interacting side chains of the 
subunit are in stick representation in the same colour coding as flurazepam. Model 
developed by Richter (Richter submitted), modified picture provided by M. Ernst. 
  
4.2. Introduction of Four Point Mutations into the β3-Minus Side Successfully 
Incorporates a Benzodiazepine Binding Site in α1β3 Receptors  
In addition to the constructs containing the triple (β3DGpCI) or quadruple 
mutations (β3DGEpCI), two other constructs were generated that contained either 
one (β3Y62F) mutation (β3D1pCI) or two mutations (β3Y62F and β3Q64A; 
β3D2pCI ) in “loop” D. These mutations seemed to be the minimum requirement for 
introducing a benzodiazepine binding at the α1-plus/β3-minus interface and should 
be ready, in case of success with the other two constructs containing three or four 
mutations. All of these constructs resulted in the expression of mutated β3 subunits 
that could assemble with α1 subunits and form receptors at the surface of HEK cells 
and Xenopus oocytes. 
Finally, due to the unclear role of the γ2-“loop” F in the binding and function of 
benzodiazepines, two additional constructs were generated, in which a total of 7 or a 
total of 12 amino acid residues of the β3-“loop” F were exchanged for the 
corresponding γ2-“loop” F residues, respectively. Since these chimeric β3 constructs 
did not result in an adequate expression and/or assembly with α1 subunits, these 
constructs were not further investigated.  
To increase our chances to rapidly obtain information on whether it is possible to 
introduce a benzodiazepine binding site into the α1-plus/β3-minus interface, in the 
present diploma work we only investigated the triple (α1β3DG) or quadruple 
mutated (α1β3DGE) recombinant receptors in pharmacological studies. For a 
complete characterization of the amino acid residues triggering allosteric action, 
positive modulation and potency, however, not only recombinant receptors α1β3DG, 
α1β3DGE, but also receptors α1β3D1 and α1β3D2, as well receptors containing 
additional mutations would have to be investigated individually. 
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Introduction of the three or the four point mutations into the β3 subunit converted the 
low potency, negative modulatory activity of flurazepam and the null modulatory 
activity of Ro15-1788 exerted in wild type α1β3 receptors, into a high potency 
positive modulation. As predicted by our structural model, the introduction of the 
fourth point mutation β3G127T increased the potency of Ro15-1788 (Fig. 3.6 D) for 
modulating GABA-induced chloride flux.  
Although the potency of flurazepam in α1β3DGE receptors is still about 100 fold 
lower than that in wild-type α1β3γ2 receptors, its efficacy for enhancing GABA-
induced chloride flux is about twice of that in wild-type receptors. This possibly 
could be explained by the fact that in α1β3DG and α1β3DGE receptors there are two 
sites with newly introduced benzodiazepine like binding properties (Fig. 1.4 C) in 
contrast to α1β3γ2 receptors that contain only the classical benzodiazepine binding 
site (Fig. 1.4 A). A simultaneous interaction of flurazepam with the two newly 
introduced benzodiazepine binding sites could thus explain the stronger efficacy of 
this compound in the mutated receptors.  
Interestingly, Ro15-1788 exhibits a lower potency but a higher efficacy for receptors 
composed of α1β3DG than for those composed of α1β3DGE subunits. This possibly 
can be explained by a simultaneous low affinity interaction of Ro15-1788 with the 
two benzodiazepine binding site-like interfaces of α1β3DG receptors. In α1β3DGE 
receptors it then has to be assumed that Ro15-1788, although interacting with higher 
affinity with the two binding sites might exhibit a reduced efficacy for enhancing 
GABA-induced chloride flux. In addition, the flat dose response curve of Ro15-1788 
for α1β3DGE receptors shown in Fig. 3.6 (D) seems to indicate that binding of 
Ro15-1788 to one of the mutated sites allosterically reduces binding to the other site.  
Since Ro15-1788 exhibits a potency of approximately 100nM for enhancing GABA-
induced chloride flux in α1β3DGE receptors, it was interesting to investigate whether 
a high affinity binding site for this compound could be demonstrated in these 
receptors. These receptors were therefore expressed in HEK cells and membranes 
from these cells were subjected to [3H]Ro15-1788 binding studies in the absence or 
presence of 100µM diazepam or Ro15-1788. Due to the low amount of [3H]Ro15-
1788 specifically bound to α1β3DGE receptors the data were quite variable in three 
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different experiments. Nevertheless, Scatchard analysis of specific [3H]Ro15-1788 
binding to α1β3DGE receptors expressed in HEK cells indicated a high affinity 
binding with KD values of 14±5nM, 42±21nM and 63±22nM (mean±S.D.), that 
could not be identified with wild-type α1β3 subunits (experiments not shown). This 
demonstrates, that local determinants within the pocket lining interface are sufficient 
to induce positive modulation and high affinity binding by benzodiazepine site 
ligands in the β3 subunit of the GABAA receptor. Compared to α1β3γ2 receptors 
exerting a KD of 3.6nM, binding of α1β3DGE receptors is 5-20 times lower. The 
average KD of approximately 40nM, however, fits quite well to the estimated potency 
of this compound of approximately 100nM in electrophysiological experiments. 
Similarly, the total number of binding sites identified (between 159-807fmoles/mg, 
depending on transfection efficiencies) in α1β3DGE receptors was less than 7.5% of 
that identified in α1β3γ2 receptors (10.280 fmoles/mg) determined in parallel 
experiments. Since in other experiments a similar expression of α1β3γ2 and 
α1β3DGE receptors was demonstrated at the cell surface, further experiments will 
have to determine whether binding to the newly introduced benzodiazepine binding 
site in α1β3DGE is labile and exhibits a high off rate, or whether only a low 
percentage of α1β3DGE receptors exhibits a conformation that allows binding of 
Ro15-1788 (Klausberger, Ehya et al. 2001).  
Since a high affinity Ro15-1788 binding site could be introduced in α1β3DGE 
receptors, it was interesting to also study the interaction of flurazepam with this 
binding site. α1β3DGE receptors were thus expressed in HEK cells and specific 
binding of 10nM or 30nM [3H]Ro15-1788 to membranes of these cells was inhibited 
by increasing concentrations of flurazepam. As shown in Fig. 3.8, flurazepam 
exhibited a Ki of 7.1µM, that is approximately 100 fold larger than that for α1β3γ2 
receptors (Ki of 75nM), and fits nicely to the potency of flurazepam for enhancing 
GABA-induced chloride flux (approximately 10µM) in electrophysiological 
experiments (Fig. 3.5 D). 
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4.3. Conclusion and Outlook 
Using predictions of our structural model of the benzodiazepine binding site of 
GABAA receptors we identified four out of 30 amino acid residues, that are different 
between the β3- and the γ2-minus side, as being important for the binding of 
benzodiazepines (for the alignment see appendix). Replacement of these four amino 
acid residues of the β3-minus side by the homologous residues of the γ2-minus side 
indeed converted a low potency negative modulatory activity of flurazepam and a 
null modulatory activity of Ro15-1788 in α1β3 receptors to a high potency positive 
modulatory effects of these compounds in the mutated α1β3DGE receptors, as 
predicted by the model. This supports previous conclusions that potency as well as 
efficacy seem to be mediated by the minus side of β3 subunits with γ-character 
(Richter submitted).  
Although featuring these highly promising characteristics, the potency, affinity, and 
efficacy of these compounds at the mutated receptors is still not identical to that at 
the wild type α1β3γ2 receptors, indicating that the benzodiazepine binding site 
engineered into the α1-plus/β3-minus interface is still incomplete. Using information 
from a combination of modelling and experimental data, further mutations enhancing 
the interaction of the compounds with the β3-minus side can be proposed, that 
hopefully will allow to engineer a benzodiazepine binding site in α1β3 receptors that 
is more similar to that in wild type α1β3γ2 receptor.  
Such mutations might also change the efficacy of Ro15-1788. This compound is a 
null modulator at the benzodiazepine binding site of GABAA receptors, but 
positively modulated the GABA currents of recombinant α1β3DG and α1β3DGE 
receptors. Such changes in the allosteric activity of Ro15-1788 were reported 
previously due to mutations in the γ subunit (Mihic, Whiting et al. 1994), leading to 
the conclusion that minor changes in the interaction of this compound with both α1 
and γ2, or α1 and β3 subunits could change its efficacy.  
The biological cause of the low potency but high efficacy of Ro15-1788 and 
flurazepam in α1β3DG receptors and high potency, low efficacy of Ro15-1788 in 
α1β3DGE receptors also is not clear. Although it was speculated above that this 
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could have been due to the presence of two engineered benzodiazepine binding sites 
in these mutated receptors, a functional coupling between some other binding sites 
might also have caused these effects and triggered structural rearrangements or 
changes in affinity (Kucken, Teissere et al. 2003). This question could be answered 
by generating α1β3DGEγ1 receptors. γ1 receptors were reported to be insensitive to 
Ro15-1788 and to exert a low affinity for flurazepam (Benke, Honer et al. 1996; 
Khom, Baburin et al. 2006). The co-expression of a γ1 together with α1 and 
recombinant β3DG or β3DGE subunits will result in only one engineered α1-
plus/β3-minus benzodiazepine binding site in these receptors that can be modulated 
by Ro15-1788 and would make it possibe to investigate the pharmacological effect 
of a single engineered benzodiazepine binding site.  
Finally, the low number of incorporated [3H]Ro15-1788 binding sites in HEK cells 
transfected with α1β3DGE receptors could either be explained by a low number of 
binding sites formed or by a high off rate of [3H]Ro15-1788. In future experiments 
this question can be answered by [3H]EBOB 
([3H]ethynylpropylbicycloorthobenzoate) binding studies. This compound is an open 
channel blocker of GABAA receptors probably binding directly into the chloride ion 
channel of these receptors (Atucha, Hammerschmidt et al. 2009). Using [3H]EBOB 
binding we thus can determine the total number of receptors formed. In case the 
number of α1β3γ2 receptors formed in HEK cells is comparable with that of 
α1β3DGE receptors, as suggested by experiment investigating cell surface 
expression of α1β3γ2, α1β3, and mutated receptors (Fig. 3.3. B), the off-rate of 
[3H]Ro15-1788 binding can be directly compared in these receptors by adding high 
concentrations of Ro15-1788 and measuring the radioactivity remaining on the 
membranes at different time points.   
Thus, although we have established a feasible and highly interesting α1β3 model 
system with an engineered high affinity benzodiazepine binding site, there are still 
several effects we cannot fully explain. Further experiments will have to be 
performed to answer all open questions.  
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